CN104582706A - 辅助癌症治疗的方法 - Google Patents

辅助癌症治疗的方法 Download PDF

Info

Publication number
CN104582706A
CN104582706A CN201380046144.4A CN201380046144A CN104582706A CN 104582706 A CN104582706 A CN 104582706A CN 201380046144 A CN201380046144 A CN 201380046144A CN 104582706 A CN104582706 A CN 104582706A
Authority
CN
China
Prior art keywords
melanoma
treatment
patient
dabrafenib
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380046144.4A
Other languages
English (en)
Chinese (zh)
Inventor
S.拉克雷
P.F.列波维奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NOVA LABORATORIES Sdn Bhd
Novartis AG
Glaxo Group Ltd
Original Assignee
GlaxoSmithKline LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50237545&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104582706(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GlaxoSmithKline LLC filed Critical GlaxoSmithKline LLC
Priority to CN201710300645.0A priority Critical patent/CN107308164A/zh
Publication of CN104582706A publication Critical patent/CN104582706A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
CN201380046144.4A 2012-09-04 2013-08-30 辅助癌症治疗的方法 Pending CN104582706A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710300645.0A CN107308164A (zh) 2012-09-04 2013-08-30 辅助癌症治疗的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261696375P 2012-09-04 2012-09-04
US61/696375 2012-09-04
PCT/US2013/057432 WO2014039375A1 (en) 2012-09-04 2013-08-30 Method of adjuvant cancer treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201710300645.0A Division CN107308164A (zh) 2012-09-04 2013-08-30 辅助癌症治疗的方法

Publications (1)

Publication Number Publication Date
CN104582706A true CN104582706A (zh) 2015-04-29

Family

ID=50237545

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380046144.4A Pending CN104582706A (zh) 2012-09-04 2013-08-30 辅助癌症治疗的方法
CN201710300645.0A Pending CN107308164A (zh) 2012-09-04 2013-08-30 辅助癌症治疗的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201710300645.0A Pending CN107308164A (zh) 2012-09-04 2013-08-30 辅助癌症治疗的方法

Country Status (20)

Country Link
US (6) US20150216868A1 (enExample)
EP (2) EP3981408A1 (enExample)
JP (3) JP2015527374A (enExample)
KR (1) KR102134585B1 (enExample)
CN (2) CN104582706A (enExample)
AU (2) AU2013313050A1 (enExample)
BR (1) BR112015004578A2 (enExample)
CA (1) CA2882437C (enExample)
CY (1) CY1124812T1 (enExample)
DK (1) DK2892535T3 (enExample)
ES (1) ES2900825T3 (enExample)
HR (1) HRP20211817T1 (enExample)
HU (1) HUE056646T2 (enExample)
IN (1) IN2015KN00449A (enExample)
LT (1) LT2892535T (enExample)
PL (1) PL2892535T3 (enExample)
PT (1) PT2892535T (enExample)
RU (1) RU2640180C2 (enExample)
SI (1) SI2892535T1 (enExample)
WO (1) WO2014039375A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110494166A (zh) * 2017-05-02 2019-11-22 诺华股份有限公司 组合疗法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104582706A (zh) 2012-09-04 2015-04-29 葛兰素史克有限责任公司 辅助癌症治疗的方法
EP3378952B1 (en) 2013-12-28 2020-02-05 Guardant Health, Inc. Methods and systems for detecting genetic variants
CA3037456A1 (en) 2016-09-19 2018-03-22 Novartis Ag Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
WO2019204399A1 (en) * 2018-04-17 2019-10-24 The University Of Chicago Methods and compositions for treating cancer
CN109106893B (zh) * 2018-11-12 2021-04-20 上海市中西医结合医院 一种调节肠道屏障功能的中药复方制剂及其制备方法
EP4563150A3 (en) 2019-05-13 2025-07-23 Novartis AG New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
EP4073102A4 (en) * 2019-12-12 2024-05-08 Ting Therapeutics LLC Compositions and methods for the prevention and treatment of hearing loss
US20250032494A1 (en) 2021-12-06 2025-01-30 My Personal Therapeutics Ltd A combination treatment for cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101006086A (zh) * 2004-06-11 2007-07-25 日本烟草产业株式会社 用于治疗癌症的5－氨基－2,4,7－三氧代－3,4,7,8－四氢－2H－吡啶并[2,3－d]嘧啶衍生物和相关化合物
WO2011047238A1 (en) * 2009-10-16 2011-04-21 Glaxosmithkline Llc Combination
CN102083312A (zh) * 2008-05-06 2011-06-01 葛兰素史密丝克莱恩有限责任公司 苯磺酰胺噻唑和噁唑化合物
WO2012095505A1 (en) * 2011-01-12 2012-07-19 Boehringer Ingelheim International Gmbh Anticancer therapy with dual aurora kinase / mek inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG166775A1 (en) * 2005-02-18 2010-12-29 Abraxis Bioscience Llc Combinations and modes of administration of therapeutic agents and combination therapy
CN104582706A (zh) 2012-09-04 2015-04-29 葛兰素史克有限责任公司 辅助癌症治疗的方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101006086A (zh) * 2004-06-11 2007-07-25 日本烟草产业株式会社 用于治疗癌症的5－氨基－2,4,7－三氧代－3,4,7,8－四氢－2H－吡啶并[2,3－d]嘧啶衍生物和相关化合物
CN102083312A (zh) * 2008-05-06 2011-06-01 葛兰素史密丝克莱恩有限责任公司 苯磺酰胺噻唑和噁唑化合物
WO2011047238A1 (en) * 2009-10-16 2011-04-21 Glaxosmithkline Llc Combination
WO2012095505A1 (en) * 2011-01-12 2012-07-19 Boehringer Ingelheim International Gmbh Anticancer therapy with dual aurora kinase / mek inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110494166A (zh) * 2017-05-02 2019-11-22 诺华股份有限公司 组合疗法
US12036227B2 (en) 2017-05-02 2024-07-16 Novartis Ag Combination therapy

Also Published As

Publication number Publication date
CY1124812T1 (el) 2022-11-25
US10869869B2 (en) 2020-12-22
KR20150047619A (ko) 2015-05-04
EP3981408A1 (en) 2022-04-13
JP6511117B2 (ja) 2019-05-15
SI2892535T1 (sl) 2022-01-31
IN2015KN00449A (enExample) 2015-07-17
CA2882437C (en) 2021-03-02
EP2892535A1 (en) 2015-07-15
PT2892535T (pt) 2021-12-15
EP2892535B1 (en) 2021-09-22
US20200054641A1 (en) 2020-02-20
BR112015004578A2 (pt) 2017-07-04
HUE056646T2 (hu) 2022-02-28
AU2016244279A1 (en) 2016-11-03
US20180338979A1 (en) 2018-11-29
AU2016244279B2 (en) 2018-01-04
EP2892535A4 (en) 2016-04-13
AU2013313050A1 (en) 2015-03-26
US20210060021A1 (en) 2021-03-04
LT2892535T (lt) 2021-12-10
RU2015105821A (ru) 2016-10-20
WO2014039375A1 (en) 2014-03-13
JP6684941B2 (ja) 2020-04-22
JP2018058859A (ja) 2018-04-12
HRP20211817T1 (hr) 2022-03-04
US20150216868A1 (en) 2015-08-06
JP2019142899A (ja) 2019-08-29
US20230330091A1 (en) 2023-10-19
JP2015527374A (ja) 2015-09-17
ES2900825T3 (es) 2022-03-18
KR102134585B1 (ko) 2020-07-17
HK1206642A1 (en) 2016-01-15
PL2892535T3 (pl) 2022-01-31
CN107308164A (zh) 2017-11-03
DK2892535T3 (da) 2022-01-03
CA2882437A1 (en) 2014-03-13
US20170202842A1 (en) 2017-07-20
RU2640180C2 (ru) 2017-12-26

Similar Documents

Publication Publication Date Title
US10869869B2 (en) Method of adjuvant cancer treatment
US10357494B2 (en) Combination therapy comprising varlitinib and an anticancer agent
EP3443962B1 (en) Quinoline derivative for treating gastric cancer
TW201839399A (zh) 癌症治療
TW201919615A (zh) 用於治療tnbc的化合物
WO2018214925A1 (zh) 用于治疗结直肠癌的喹啉衍生物
TW202329946A (zh) 用於治療癌症之方法及包含cdk2抑制劑之給藥方案
US20210205272A1 (en) Dosing regimens for treatment of solid tumors having one or more genetic alterations in fgfr1, fgfr2, and/or fgfr3
HK40070843A (en) Dabrafenib and trametinib in a method of adjuvant cancer treatment
US20220073642A1 (en) Methods of using surufatinib in treating advanced pancreatic and extra-pancreatic neuroendocrine tumors
HK1206642B (en) Method of adjuvant cancer treatment
WO2025245463A1 (en) Combination therapies
CN118354772A (zh) 治疗头颈癌的方法
CN117940132A (zh) Erk1/2和kras g12c抑制剂组合疗法
WO2017030146A1 (ja) 胆道癌治療剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20160516

Address after: Basel, Switzerland

Applicant after: NOVARTIS AG

Address before: Basel, Switzerland

Applicant before: NOVA LABORATORIES SDN BHD

Effective date of registration: 20160516

Address after: Basel, Switzerland

Applicant after: NOVA LABORATORIES SDN BHD

Address before: British Ahmed Sykes

Applicant before: Glaxo Group Ltd.

Effective date of registration: 20160516

Address after: British Ahmed Sykes

Applicant after: GLAXO Group Ltd.

Address before: Delaware

Applicant before: GLAXOSMITHKLINE LLC

RJ01 Rejection of invention patent application after publication

Application publication date: 20150429

RJ01 Rejection of invention patent application after publication